General
Preferred name
NEOSTIGMINE
Synonyms
NEOSTIGMINE BROMIDE ()
NEOSTIGMINE METHYLSULFATE ()
CHEMBL54126 ()
Normastigmin ()
Hodostin ()
Syntostigmin ()
neostigmine methylsulfate, Flamel Technologies ()
Neostigmine (Bromide) ()
Neostigmine (methyl sulfate) ()
Eustigmin bromide ()
Neoserine bromide ()
Neostigmine methyl sulfate, Syntostigmin, Neostigmeth ()
Neostigmine Iodide ()
Neostigmine methyl sulfate ()
Bloxiverz ()
Robinul-Neostig ()
Neostigmini metilsulfas ()
Intrastigmina ()
NSC-93753 ()
Neostigmine methylsulfate component of prevduo ()
Neostigmine methylsulphate ()
Neostigmine metilsulfate ()
NSC-757233 ()
Neoproserine ()
Bromuro de neostigmina ()
Syntostigmin bromide ()
Kirkstigmine bromide ()
Neo proserine ()
Neostigmini bromidum ()
Vagostigmin ()
Bromure de neostigmine ()
Miostin ()
Neostigmine cation ()
Neostigmine hydroxide ()
Neostigmine ion ()
Neostigmine (cation) ()
Neostigmine ()
P&D ID
PD009515
CAS
51-60-5
114-80-7
59-99-4
1212-37-9
Tags
available
drug
drug candidate
probe
Approved by
FDA
First approval
2013
Drug indication
Myasthenia gravis
morbid obesity
Drug Status
approved
investigational
vet_approved
Max Phase
4.0
2.0
Probe info
Probe type
calculated probe
Probe sources
Tool Compound Set
Probe targets
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Neostigmine methyl sulfate is a reversible inhibitor of acetylcholinesterase, can not cross the blood-brain barrier.
PRICE 29
DESCRIPTION Neostigmine (Eustigmin) Bromide is an orally active and reversible cholinesterase inhibitor that acts on myasthenia gravis to prolong and intensify the muscarinic and nicotinic effects of acetylcholine. Neostigmine Bromide can be used in anesthesia to reverse the neuromuscular blockade produced by competitive neuromuscular blockers[1][2][3][4].
PHARMACODYNAMICS Neostigmine is a cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier. By inhibiting acetylcholinesterase, more acetylcholine is available in the synapse, therefore, more of it can bind to the fewer receptors present in myasthenia gravis and can better trigger muscular contraction.; ;
DESCRIPTION Neostigmine is a peripherally acting, reversible acetylcholinesterase (ACHE) inhibitor. Marketed formulations contain neostigmine bromide (PubChem CID 8246) or neostigmine methylsulfate (CID 5824). (GtoPdb)
DESCRIPTION Neostigmine methylsulfonate is a reversible inhibitor of acetylcholinesterase. It is used for the symptomatic treatment of myasthenia gravis by improving muscle tone. (Enamine Bioactive Compounds)
DESCRIPTION Neostigmine methyl sulfate (Syntostigmin) is a reversible inhibitor of acetylcholinesterase, can not cross the blood-brain barrier, used in the treatment of myasthenia gravis. (TargetMol Bioactive Compound Library)
DESCRIPTION Neostigmine bromide(Prostigmin) is a reversible acetylcholinesterase inhibitor and a parasympatho-mimetic. (BOC Sciences Bioactive Compounds)
DESCRIPTION Reversible inhibitor of acetylcholinesterase (LOPAC library)
DESCRIPTION This active molecular is a reversible acetylcholinesterase inhibitor as a parasympathomimetic compound under the development of Flamel Technologies. Neostigmine Iodide is used to improve muscle tone in people with myasthenia gravis and it can also be used to reverse the effects of non-depolarizing muscle relaxants at the end of the surgery. Neostigmine Iodide also can be applicated for urinary retention resulting from general anesthesia and to treat curariform drug toxicity. (BOC Sciences Bioactive Compounds)
Cell lines
0
Organisms
3
Compound Sets
29
AdooQ Bioactive Compound Library
A10635
BOC Sciences Bioactive Compounds
neostigmine-bromide-cas-114-80-7-item-84-290531
neostigmine-iodide-cas-1212-37-9-item-475153
Cayman Chemical Bioactives
23501
ChEMBL Approved Drugs
CHEMBL211471
CHEMBL278020
ChEMBL Drugs
CHEMBL211471
CHEMBL54126
CHEMBL278020
Drug Repurposing Hub
DrugBank
DB01400
DrugBank Approved Drugs
DB01400
DrugCentral
1897
DrugCentral Approved Drugs
1897
DrugMAP
DM6T2J3
DrugMAP Approved Drugs
DM6T2J3
DrugMatrix
Enamine Bioactive Compounds
EBC-08150
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS101353
Guide to Pharmacology
8993
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL211471
CHEMBL54126
CHEMBL278020
MedChem Express Bioactive Compound Library
HY-B1206
HY-B0423
NCATS Inxight Approved Drugs
3982TWQ96G
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
hodostin
Neostigmine-bromide(Prostigmin)
TargetMol Bioactive Compound Library
T1612
The Spectrum Collection
Tool Compound Set
External IDs
90
Properties
(calculated by RDKit )
Molecular Weight
223.14
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
0
Rotatable Bonds
2
Ring Count
1
Aromatic Ring Count
1
cLogP
1.94
TPSA
29.54
Fraction CSP3
0.42
Chiral centers
0.0
Largest ring
6.0
QED
0.72
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Selectivity
Acetylcholinesterase
Target
AChE
AChR
Cholinesterase (ChE)
MOA
AChR inhibitor
Acetylcholinesterase Inhibitors
Acetylcholinesterase inhibitor
Member status
member
Indication
myasthenia gravis
Pathway
Neuroscience
Neuronal Signaling
Therapeutic Class
Parasympathomimetics
Solubility
Soluble in DMSO
Source data